Progress of Tumor Infiltrating Lymphocytes in Immunotherapy of Triple Negative Breast Cancer.
10.3881/j.issn.1000-503X.12666
- Author:
Jia-Lin ZHAO
1
;
Xue-Jing WANG
2
;
Xi CAO
2
;
Qiang SUN
2
Author Information
1. Department of Ultrasound,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
2. Department of Breast Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- Keywords:
immunotherapy;
prognosis;
triple negative breast cancer;
tumor infiltrating lymphocytes
- MeSH:
Biomarkers, Tumor;
China;
Female;
Humans;
Immunotherapy;
Lymphocytes, Tumor-Infiltrating;
Prognosis;
Triple Negative Breast Neoplasms/therapy*
- From:
Acta Academiae Medicinae Sinicae
2021;43(3):475-480
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer has become the most common cancer for women in China.Lack of effective therapeutic targets,triple negative breast cancer(TNBC)has poorer prognosis compared with other subtypes of breast cancer.Tumor infiltrating lymphocytes(TILs)are a group of heterogeneous lymphocytes around the tumor,which are believed as immunoreactive products of host immune response to tumor antigens.At present,there have been reports on the predictive effect of TILs on the prognosis of breast cancer,and the available studies focus mainly on TNBC.This article briefly reviews the recent progress of tumor infiltrating lymphocytes in immunotherapy of TNBC.
